Shots:

• The BTD is based on P-II results that demonstrated improvement of the 1EPs locoregional control rate @18mos. after CRT (21% improvement vs. control arm) and a marked PFS benefit vs the CRT + PBO arm after a 2-year follow-up period
• The BTD reaffirms that Debio 1143 has the potential to offer benefit over the current SOC in LA-SCCHN- responding to the high unmet need in this debilitating cancer type
• Debio 1143 is a potential first-in-class oral antagonist of IAPs- sensitizes tumor cells to radio-CT by promoting programmed cell death and fostering anti-tumor immunity

 ­ Ref: PRNewswire | Image: Debiopharm